| 摘要 |
<p>Therapeutic combinations of an antisense oligonucleotide and another, non-oligonucleotide chemotherapeutic agent are provided which allows for a reduced dosage of the non-oligonucleotide agent, and hence, reduced toxicity to the host. The antisense oligonucleotide component has a nucleotide sequence complementary to at least a portion of the mRNA transcript of a target oncogene or proto-oncongene, the amplification or expression of which is associated with the particular neoplastic disease under treatment. The combination is particularly useful in treating leukemias, more particularly as a bone marrow purging agent.</p> |
